Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. Our mission is to extend and improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects normally associated with cancer treatment.
Rexahn is focused on discovering and developing new treatments that have the potential to improve the clinical outcome in cancers that are difficult to treat. Through targeting cancer therapies to tumor cells, we aim to minimize effects on healthy tissue and improve safety and quality of life relative to other treatment options.
We believe that optimum anticancer efficacy will be achieved through using combinations of drugs that work in different ways to kill cancer cells and inhibit tumor growth. Rexahn's targeted therapies act synergistically with other anticancer agents and with immunotherapy in preclinical models. We are currently evaluating the combination approach in our clinical studies.
American lives are claimed by cancer every year, according to the Centers for Disease Control and Prevention.
Deaths in 2015 were caused by cancer, according to a survey done by the World Health Organization in 2018.
New cancer cases will be diagnosed in the United States in 2018, according to a 2018 report by the American Cancer Society.
Rexahn has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0301. Our product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth, proliferation and metastasis.
| Candidate & Indication | Collaborators | Preclinical | Phase 1 | Phase 2 |
|---|---|---|---|---|
RX-3117Metastatic Pancreatic Cancer Advanced Bladder Cancer Additional Cancer Indications |
|
Preclinical complete
Preclinical complete
Preclinical in progress
|
Phase 1 complete
Phase 1 complete
Phase 1 not started
|
Phase 2 in progress
Phase 2 in progress
Phase 2 not started
|
RX-5902Metastatic Triple Negative Breast Cancer |
Preclinical complete
|
Phase 1 complete
|
Phase 2 in progress
|
|
RX-0301Hepatocellular Carcinoma |
|
Preclinical in progress
|
Phase 1 not started
|
Phase 2 not started
|
